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Abstract
Background: Hypertension is a global public health issue and is closely related to chronic kidney disorder (CKD). In people
with CKD, strict monitoring of blood pressure is an important part of therapy.
Objective: The aim of this research was to validate the iHealth Track blood pressure monitoring device for patients with CKD
according to the European Society of Hypertension International Protocol 2010 (ESH-IP2).
Methods: In total, 33 patients who received hemodialysis in Plasencia participated in the study. There were 9 successive
measurements made, which conformed to the ESH-IP2. We calculated the differences between the standard reference device
(Omron M3 Intellisense) and the test device (iHealth Track) for blood pressure and heart rate values. For 99 total comparisons
of paired measurements, we classified differences into various categories (≤5 mmHg, ≤10 mmHg, and ≤15 mmHg for blood
pressure; ≤3, ≤5, and ≤8 beats per minute for heart rate).
Results: In 90 of 99 systolic blood pressure and 89 of 99 diastolic blood pressure comparisons between the devices, measurement
differences were within 5 mmHg. In 81 of 99 heart rate comparisons between the devices, measurement differences were within
3 beats per minute. The mean differences between the test and reference standard measurements were 3.27 (SD 2.99) mmHg for
systolic blood pressure, 3.59 (SD 4.55) mmHg for diastolic blood pressure, and 2.18 (SD 2.75) beats per minute for heart rate.
We also observed that for both systolic and diastolic blood pressure, 31 of 33 participants had at least two of three comparisons
between the devices with measurement differences less than 5 mmHg. For heart rate, 28 of 33 patients had at least two of three
comparisons between the devices with measurement differences less than 3 beats per minute.
Conclusions: To our knowledge, this is the first study to show that iHealth Track meets the requirements of the ESH-IP2 in
patients with CKD. Therefore, the iHealth Track is suitable for use in renal patients.
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Introduction
Chronic kidney disorder (CKD) is a syndrome defined by
persistent alterations in renal function or structure that cause
complications in a patient's health. Some of the structural
anomalies may be tumors, cysts, malformations, or atrophies.
In addition, renal dysfunction can be manifested through
alterations in the output or grade of urine, increased risks of
intellectual disabilities in children, edema, and hypertension
[1,2].
In fact, the diseases most related with CKD are hypertension
and diabetes, especially in high- and middle-income countries
[3,4]. Hypertension may simply be a consequence of CKD [5,6]
or both a cause and consequence of CKD [7,8]. Hypertension
may be due to hypervolemia or activation of the
renin-angiotensin system or neurohumoral (catecholamine and
aldosterone) axis. In addition, sometimes high blood pressure
(BP) originates from calcineurin or corticosteroid inhibitors
used to treat underlying kidney disorders [9].
The interaction between CKD and hypertension is complex and
increases the probability of cerebrovascular and cardiovascular
problems [9-11]. In several studies, cardiovascular events and
deaths from any cause were reduced when systolic BP was <120
mmHg (compared to <140 mmHg) in patients with CKD and
hypertension but not diabetes [11-13]. Therefore, strict control
of BP is important for CKD therapy [14].
Monitoring of BP should be done with devices that are easy to
use and accurate [11,15-18]. These devices must be tested and
validated by independent experts (eg, the British Hypertension
Society [19], the Association for the Advancement of Medical
Instrumentation [20], and the European Society of Hypertension
[21,22]) with protocols validated and designed expressly for
BP monitoring [23]. The purpose of this study was to validate
the iHealth Track BP monitoring device for self-measurement
in patients with CKD, according to the European Society of
Hypertension International Protocol 2010 (ESH-IP2). Therefore,
the hypothesis of this study was that iHealth Track would be
valid for the self-measurement of BP and heart rate (HR) in
renal patients according to the ESH-IP2.
Methods
Ethical Information
The study protocol was approved by the Institutional Local
Research and Ethical Committee (Universidad de Extremadura,
Badajoz, Spain; record number 152/2019). In conducting this
study, we complied with the ethical principles of the Declaration
of Helsinki [24], including any emendations between 2000 and
2013. All participants provided signed informed consent prior
to participating in this study.
The Devices
Omron M3 Intellisense
The standard device we used for reference was the Omron M3
Intellisense (Omron Healthcare, Kyoto, Japan), which has been
validated according to the International Protocol for the general
population [25] as well as CKD patients [26]. We purchased
the Omron M3 Intellisense monitor from a local marketplace.
The Omron M3 Intellisense is an oscillometric and automated
upper-arm device for home BP monitoring. The device’s
standard arm cuff is 22 to 32 cm around, and a large cuff is also
available for arm circumferences of 32 to 42 cm. The device
uses IntelliSense technology to produce comfortable, controlled
inflation without the need for pressure presetting or reinflation.
iHealth Track
The test device was the iHealth Track automatic appliance with
serial number KN-550BT (iHealthLabs Europe, Paris, France),
which registers brachial BP with the oscillometric protocol. It
detects BP between the range of 0 mmHg to 300 mmHg
(measuring precision ±3 mm Hg) and HRs within the range of
40 to 180 beats per min (measurement precision ±5%). The
device’s arm cuff is 22 to 42 cm around.
The device’s liquid crystal display screen shows the measured
systolic (S) BP, diastolic (D) BP, and HR values. The device
unit has enough memory for 99 recordings. Additionally, this
device unit can be used with Apple Bluetooth 4.0 devices and
certain Android Bluetooth 4.0 cellular phones through an
application named Health MyVitals. This means that BP and
HR data can be stored on wireless devices connected to iHealth
Track and then displayed graphically.
Patients and Recruitment
We recruited patients with CKD who attended the Fresenius
Medical Care dialysis clinic in Plasencia, Spain. A total of 33
patients who met the selection criteria participated. The inclusion
criteria were adults 25 years of age or older that received
hemodialysis. We sought at least 10 male participants and 10
female participants. The exclusion criteria, which were created
according to the ESH-IP2 [21,22], were sustained arrhythmia,
circulatory problems where use of the cuff is contraindicated,
and pregnancy.
Research Protocol
The professional validation team consisted of 2 nurses with
senior experience (more than 6 years) in BP measurement. The
measurement area was correctly conditioned to a suitable
temperature, and factors that could affect the records, such as
noise or distractions, were removed [21,22]. All measurements
were made in the same room. The color of the room was white.
After dialysis, each patient first reported information regarding
their sex, age, height, and dry weight. In addition, we calculated
participants’ BMI using Quetelet´s index in kg/m2. The
circumference of the patient’s arm was measured to ensure that
the cuff size was adequate.
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Next, patients sat in the measurement room and BP
measurements were started after a 10- to 15-minute rest period.
Each patient was seated in a standard-size plastic chair with a
backrest and armrests.
In total, 9 consecutive measurements were made on each
participant with the Omron M3 Intellisense (5) and the iHealth
Track (4) as follows [21,22]:
• (BPA): input BP, by the standard device unit
• (BPB): device BP detection by the test device unit
• (BP1): standard device unit
• (BP2): test device unit
• (BP3): standard device unit
• (BP4): test device unit
• (BP5): standard device unit
• (BP6): test device unit
• (BP7): standard device unit
During the measurements, participants remained calm, quiet,
seated, and still. Participants kept their backs straight and feet
on the floor in a parallel position (ie, without crossing their
legs). They rested their arms on a flat surface with their palms
facing upwards and their elbows slightly flexed so that their
fists were at the height of their hearts.
BP records were made at heart level on the right arm in 31
participants and on the left arm in 2 participants (because of an
arteriovenous fistula on the right arm). The standard cuff size
(22-32 cm) for the Omron M3 Intellisense was used for all men
(20). For women, the standard cuff (22-32 cm) was used for 11
participants, and the large cuff (32-42 cm) was used for 2
participants. Since the iHealth Track has only one cuff size
(22-42 cm), all measurements were taken with it. The interval
between one measurement and the next was 30 to 60 seconds
[22].
All measurements were made for each participant during their
hemodialysis appointment, after the dialysis was complete. The
relative values were then used to calculate the mean difference
between the reference device readings and the test device
readings. All participants were receiving hemodialysis in the
Fresenius Medical Care dialysis clinic in Plasencia.
Data Analysis
We analyzed the data with the software SPSS Statistics, version
19.0 (IBM, Armonk, New York). We reported the findings as
mean (SD).
According to the ESH-IP2, the accuracy of a device is based
on a comparison between the test device (iHealth Track) and
the standard reference device (Omron M3 Intellisense)
measurements. For each participant, we first compared
measurements BP2, BP4, and BP6 with measurements BP1,
BP3, and BP5, respectively, and then compared measurements
BP3, BP5, and BP7 with each other. The most favorable
comparisons were used.
In our comparisons, we classified differences for both SBP and
DBP, separately, by whether paired values were within 5, 10,
or 15 mmHg [22], and whether paired values for HR were within
3, 5, or 8 beats per minute (BPM). We determined whether the
test device passed the ESH-IP validation protocol. Part 1 of the
validation process concerns the number of differences allowed
in the specified ranges of each measure (SBP, DBP, and HR)
for comparisons of individual measurements between devices
(99 measurements) [22]. Part 2 concerns the comparisons
between devices of each measure for individual participants
(33) [22].
Moreover, we produced Bland-Altman plots [27,28] to display
the agreement between the two devices (the iHealth Track and
the Omron M3 Intellisense). These plots show the difference
between each pair of measurements on the y-axis against the




Of the 34 participants we recruited, 33 completed the study
successfully (one was excluded for device failure). The 33
participants included 20 men and 13 women. Table 1 shows a
summary of their biometric characteristics.
Table 1. Participants’ biometric characteristics.
Females (N=13)Males (N=20)Total sample (N=33)Variables
RangeMean (SD)RangeMean (SD)RangeMean (SD)
47.0-88.072.77 (12.57)47.0-85.070.25 (11.42)47.0-88.071.24 (11.76)Age (years)
46.0-101.070.94 (20.16)47-100.070.18 (12.95)46.0-101.070.48 (15.87)Weight (kg)
141.0-174.0154.77 (11.24)160.0-180.0167.10 (4.58)141.0-180.0162.24 (9.87)Height (cm)
19.0-44.029.84 (8.90)18.0-33.025.07 (4.08)18.0-44.026.95 (6.72)BMI (kg/m2)
220.0-350.0265.0 (33.12)220.0-320.0264.75 (26.13)220.0-350.0265.0 (33.12)Arm circumference (mm)
Blood Pressure Measurements
The iHealth Track BP device validation results were taken in
accordance with the ESH-IP2. The mean differences between
the reference standard and test devices were 3.27 (SD 2.99)
mmHg for SBP and 3.59 (SD 5.28) mmHg for DBP. In 90 out
of 99 SBP and 89 out of 99 DBP comparisons between the
devices, measurement differences were within 5 mmHg,
exceeding the ESH-IP thresholds (>72 comparisons for SBP
and >64 comparisons for DBP). Additionally, in 95 out of 99
SBP and 94 out of 99 DBP comparisons between the devices,
measurement differences were within 10 mmHg, also exceeding
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the ESH-IP thresholds (>86 comparisons for SBP and >80
comparisons for DBP). Moreover, in 98 out of 99 SBP and 94
out of 99 DBP comparisons between the devices, measurement
differences were within 15 mmHg, which again surpasses the
ESH-IP thresholds (>95 comparisons for SBP and >92
comparisons for DBP). Therefore, the iHealth Track passed part
1 of the validation protocol for BP monitoring.
Regarding part 2 of the ESH-IP2, 31 out of 33 participants had
at least two of the three comparisons between devices with
measurement differences within 5 mmHg for both SBP and
DBP, exceeding the ESH-IP threshold (>23 participants). One
participant had all three comparisons for both SBP and DBP
with measurement differences greater than 5 mmHg, which is
less than the ESH-IP maximum of 3 participants. Given these
results, the iHealth Track also passed part 2 of the validation
protocol for BP. Thus, because the iHealth Track passed parts
1 and 2 of the BP validation protocol, it passed part 3 of the
protocol, overall validation.
Heart Rate Measurements
The validation findings for the iHealth Track HR monitoring
device were taken according to the ESH-IP2. The mean
difference between the reference standard and test devices was
2.18 BPM (SD 2.75). In comparisons between devices, 81 out
of 99 pairs of measurements were within 3 BPM, 91 out of 99
were within 5 BPM, and 96 out of 99 were within 8 BPM. These
results indicate that the iHealth Track passed part 1 of the
validation protocol for HR.
Regarding part 2 of the ESH-IP2, 28 out of 33 patients had at
least two of three comparisons between devices with
measurement differences within 3 BPM, which exceeds the
ESH-IP threshold (>23 participants). Only 2 participants had
all three HR comparisons with measurement differences greater
than 3 BPM, which is less than the ESH-IP maximum of 3
participants. Therefore, the iHealth Track passed part 2 of the
HR validation protocol and, consequently, part 3 (overall
validation) as well.
The Bland-Altman graphs (Figures 1-3) give further information
on the performance of the iHealth Track device. The graphs
show that the measurement differences between the devices
were fairly constant across the ranges of SBP, DBP, and HR.
Figure 1. Bland-Altman graph of systolic blood pressure differences between the iHealth Track and the Omron M3.
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Figure 2. Bland-Altman graph for diastolic blood pressure differences between the iHealth Track and the Omron M3.
Figure 3. Bland-Altman graph for heart rate differences between the iHealth Track and the Omron M3.
Discussion
This study is the first to validate the accuracy of the iHealth
Track device for BP and HR recordings in patients with CKD.
The results indicate that the iHealth Track, as used in renal
patients, passed the ESH-IP2 validation requirements. We
previously validated the iHealth Track device for the general
population following ESH-IP2 [29].
This study showed two limitations. Although the iHealth Track
has been validated in the general population and now in patients
with CKD, we cannot necessarily extrapolate our results to other
specific populations. In addition, patients with CKD have stiffer
arteries than other people [9,11,14]. We did not investigate
arterial stiffness, but it would be useful to assess it in future
validation studies.
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The ESH-IP2 for home BP monitoring highlights the need for
specific validation in patients with end-stage renal disease
[14,30] as strict control of hypertension is required in these
patients [9,14].
However, there are few devices that have been validated in
patients with renal disease [26,31-34]. Akpolat et al [26]
validated Omron M3 HEM-7051 in patients with CKD
according to the ESH-IP2 revision. They used the mercury
sphygmomanometer as their standard reference device and
included 66 participants, rather than 33. The results were similar
to ours, since both studies passed the ESH-IP revision’s two
phases of validation. However, the number of differences
included in the category of 5 mmHg according to the ESH-IP2
were better for the iHealth Track for both SBP and DBP (ie,
iHealth Track achieved higher differences than Omron). The
differences obtained with the HRs cannot be contrasted as HR
was not measured by Akpolat et al. Likewise, our findings
cannot be compared with the rest of the validation studies found
[31-34], since none followed the ESH-IP2 validation
requirements. We believe that more validation studies for BP
monitoring devices are necessary for patients with CKD.
The purpose of the ESH-IP2 was to simplify the previous
protocols of the British Hypertension Society (BHS) [19] and
the Association for the Advancement of Medical Instrumentation
(AAMI) [20]. However, the protocol does have some
shortcomings. First, the major limitation is that it is
underpowered with only 33 participants (99 measures) required
rather than the 85 participants (255 measures) required by the
previous AAMI and BHS validation protocols [19,20]. Second,
the ESH-IP2 does not indicate the number of validation studies
needed to establish the accuracy of a device. According to some
experts, at least two validation studies should be performed in
different centers and in different populations before accepting
the device as accurate [35]. Therefore, it is valuable to evaluate
BP devices in diverse specific populations before they are used
widely in clinics and homes. Third, the ESH-IP2 imposes certain
gender requirements and limits validation studies to individuals
older than 25 years who have BPs within specific ranges.
Therefore, device accuracy remains unknown in children,
adolescents, young adults, and patients with extreme BP values.
Finally, the ESH-IP2 does not mention explicit criteria for
validation in specific populations. Following the start of our
study, in March 2019, the AAMI/ESH/ISO Universal Standard
was published as the recommended standard for validation of
BP measuring devices. [36]. This standard includes criteria for
the validation of BP devices in specific populations. This will
be considered in our future validations.
Our study is the first to show that the iHealth Track device meets
the requirements of ESH-IP2 in patients with CKD. Future
versions of the ESH-IP should include explicit criteria for
validation in specific populations. Validation of this device
would be valuable in other specific populations such as pregnant
women, older adults, and patients with arrhythmias.
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